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http://dx.doi.org/1patients with dyslipidemia and/or hypertension receiving phentermine (PHEN) and top-
iramate extended-release (TPM ER). In the 56-week, randomized, double-blind, placebo-
controlled, multicenter CONQUER trial, PHEN/TPM ER demonstrated signiﬁcant weight
loss compared with placebo in overweight or obese participants with ‡2 weight-related
co-morbidities. Participants with body mass indexes of 27 to 45 kg/m2 were randomized to
placebo, PHEN 7.5 mg/TPM ER 46 mg, or PHEN 15 mg/TPM ER 92 mg; participants also
received lifestyle modiﬁcation counseling. Primary end points were percentage weight loss and
the proportion of participants achieving ‡5% weight loss. Additional end points were changes
in lipid variables in the dyslipidemia population and blood pressure in the hypertensive
population, stratiﬁed by treatment and magnitude of weight loss. PHEN/TPM ER produced
signiﬁcantly greater dose-related mean percentage weight loss compared with placebo in the
subgroups of participants with dyslipidemia and those with hypertension. Regardless of
treatment group assignment, participants with dyslipidemia who lost ‡5% of their baseline
weight experienced signiﬁcantly greater reductions in triglycerides (L14.5% toL39.8%), and
in nonehigh-density lipoprotein cholesterol (L9.4% to L14.8%) than those losing <5% of
their weight (p <0.05). Similarly, participants with hypertension at baseline showed reduced
systolic blood pressure byL7.5 toL11.8 mm Hg (p <0.001 vs those with <5% weight loss). In
conclusion, the dose-related weight loss induced by PHEN/TPM ER treatment was accom-
panied by signiﬁcant improvements in cardiovascular disease risk factors in participants who
had dyslipidemia or hypertension at baseline, suggesting that facilitating weight loss by
augmenting lifestyle changes with pharmacotherapies may decrease the risk for cardiovascular
disease in obese and overweight patients with co-morbidities. 2013 Elsevier Inc. Open access under CC BY (Am J Cardiol 2013;111:1131e1138)-NC-ND license.Pharmacotherapy with phentermine (PHEN) and top-
iramate extended-release (TPM ER) has been shown to
reduce weight in obese patients and was approved in 2012
as an adjunct to a reduced-calorie diet and increased phys-
ical activity for long-term weight management in adult
patients with initial body mass indexes30 kg/m2 (obese) or
27 kg/m2 (overweight) in the presence of 1 weight-
related co-morbidity.1e4 The combination therapy includes
PHEN hydrochloride, a centrally acting appetite suppressant,
approved by the US Food and Drug Administration for the
short-term (a few weeks; up to 37.5 mg/day) treatment of
obesity,5,6 and TPM, a centrally acting agent approved inase formulation for the treatment of epilepsy
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Open access under CC BY-NC-ND license.and the prevention of migraine headaches.7 This combination
has been shown to result in weight loss and improvements in
lipids, glycemic variables, and blood pressure in obese
patients in randomized studies, but it is not approved by the
Food and Drug Administration for weight reduction.8e10 The
56-week phase 3 CONQUER study demonstrated that the
administration of the once-daily, extended-release combina-
tion of PHEN/TPM ER as an adjunct to lifestyle intervention
had good tolerability and was effective in reducing weight
and improving cardiometabolic risk factors in overweight
and obese patients with 2 weight-related co-morbidities.2
In the present subanalysis, we evaluated changes in cardio-
vascular disease risk factors in subgroups of participants with
dyslipidemia and/or hypertension at the start of the study.
Methods
The design and main results of the study have been pub-
lished previously.2 Brieﬂy, CONQUER was a 56-week,
randomized, double-blind, placebo-controlled, multicenter (93
United States sites) study that evaluated weight loss in over-
weight and obese participants with multiple weight-related
co-morbidities who were treated with PHEN/TPM ER as an
adjunct to lifestyle modiﬁcation. The trial was approved by
each site’s institutional review board, and all participants
www.ajconline.org
Table 1
Baseline characteristics
Variable Overall Population Subgroup With Dyslipidemia Subgroup With Hypertension
N Value n Value n Value
Age (yrs) 2,487 51.1  10.4 1,341 50.7  10.5 1,305 53.0  9.8
Women 2,487 1,737 (69.8%) 1,341 867 (64.7%) 1,305 860 (65.9%)
White 2,487 2,140 (86.0%) 1,341 1,240 (92.5%) 1,305 1,087 (83.3%)
Black 2,487 292 (11.7%) 1,341 64 (4.8%) 1,305 191 (14.6%)
Hispanic or Latino 2,487 328 (13.2%) 1,341 184 (13.7%) 1,305 132 (10.1%)
Not Hispanic or Latino 2,487 2,159 (86.8%) 1,341 1,157 (86.3%) 1,305 1,173 (89.9%)
Weight (kg) 2,485 103.1  17.9 1,341 103.7  18.1 1,305 104.4  18.4
Body mass index (kg/m2) 2,485 36.6  4.5 1,341 36.5  4.5 1,305 36.7  4.6
Waist circumference (cm) 2,485 113.2  12.3 1,341 113.7  12.0 1,305 114.0  12.6
Blood pressure (mm Hg)
Systolic 2,485 128.4  13.5 1,341 127.6  13.4 1,305 134.2  13.0
Diastolic 2,485 80.6  9.1 1,341 80.4  9.1 1,305 83.7  9.1
Heart rate (beats/min) 2,485 72.3  10.0 1,341 72.8  10.3 1,305 71.6  10.4
Non-HDL cholesterol (mg/dl) 2,485 155.6  39.7 1,341 166.7  40.7 1,305 153.8  39.1
LDL cholesterol (mg/dl) 2,480 123.1  35.4 1,336 124.3  37.7 1,303 123.0  35.7
HDL cholesterol (mg/dl) 2,485 48.9  13.6 1,341 44.4  11.4 1,305 49.6  13.7
Triglycerides (mg/dl) 2,485 162.5  74.1 1,341 212.5  64.0 1,305 154.0  68.3
Fasting glucose (mg/dl) 2,476 106.1  22.2 1,335 107.4  23.4 1,301 105.6  20.7
Glycosylated hemoglobin (%) 2,478 5.9  0.8 1,339 5.9  0.8 1,302 5.9  0.7
Fasting insulin (mIU/ml) 2,467 18.1  15.1 1,335 19.8  14.8 1,295 18.4  15.2
High-sensitivity C-reactive protein (mg/L) 2,473 6.6  10.1 1,337 6.6  11.5 1,297 6.5  11.4
Adiponectin (mg/mL) 2,001 8.0  4.6 1,066 7.1  3.9 1,058 8.1  4.7
Fibrinogen (mg/dl) 2,479 457.4  92.4 1,340 448.9  90.7 1,301 458.5  92.0
10-year Framingham score 1,887 4.8  5.7 1,024 5.6  6.3 1,004 5.8  6.1
10-year Reynolds risk score 2,051 5.9  6.2 1,112 6.5  6.5 1,068 7.2  6.9
Data are expressed as mean  SD or as number (percentage).
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
1132 The American Journal of Cardiology (www.ajconline.org)provided written informed consent. The study was conducted
from November 1, 2007 to June 30, 2009. This trial is regis-
tered with ClinicalTrials.gov (NCT00553787).
Participants were eligible to enroll in the study if they
had body mass indexes of 27 to 45 kg/m2, were 18 to
70 years of age, and had 2 weight-related co-morbidities.2
Hypertension was deﬁned as systolic blood pressure 140
and 160 mm Hg (or 130 and 160 mm Hg if diabetic),
diastolic blood pressure 90 and 100 mm Hg (or 85 and
100 mm Hg if diabetic), or the use of 2 antihypertensive
medications. Although the study protocol deﬁned dyslipi-
demia as triglycerides 200 and 400 mg/dl (or using 2
lipid-lowering medications), for the purposes of this
subgroup evaluation, analyses were performed using a lower
triglyceride threshold (150 mg/dl) on the basis of estab-
lished criteria.11 Detailed inclusion and exclusion criteria for
this study have been described previously.2
After a 2-week screening period, eligible participants
were randomly assigned in a 2:1:2 ratio to receive blinded,
once-daily treatment with placebo, PHEN 7.5 mg/TPM
ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92).
They then underwent a blinded 4-week titration period and
were maintained for 52 weeks at the randomized dose.2
Randomization was stratiﬁed by gender and diabetic status.
All participants received standardized diet and lifestyle
modiﬁcation counseling at each study visit, including a
500 kcal/day reduction in caloric intake, on the basis
of the LEARN (Lifestyle, Exercise, Attitudes, Relationships,
Nutrition) program.12 Co-morbidities were actively managedaccording to national guidelines, including the careful
monitoring and adjustment of concomitant medications.
Predeﬁned end points in the overall population were mean
percentage weight loss and the proportion of participants
achieving 5% weight loss. In this post hoc analysis of
subjects with dyslipidemia, mean percentage weight loss,
changes in lipid variables, concomitant lipid-lowering
medications, and serum inﬂammatory biomarkers (adipo-
nectin, ﬁbrinogen, and high-sensitivity C-reactive protein)
were evaluated. In the post hoc analysis of subjects with
hypertension, mean percentage weight loss, changes in blood
pressure, achievement of the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure recommended blood
pressure goal of <140/90 mm Hg (or <130/80 mm Hg in
patients with type 2 diabetes mellitus),13 and concomitant
antihypertensive medication use were assessed. All addi-
tional end points were also stratiﬁed by degree of weight loss
(<5%, 5% to <10%, 10% to <15%, and 15%). Safety
assessments included physical examination, incidence of
adverse events, changes in laboratory safety parameters, vital
signs including heart rate, and electrocardiographic param-
eters (RR interval, QRS duration, and QT interval).2 Subjects
with clinically signiﬁcant abnormal electrocardiographic
ﬁndings at baseline were excluded from the study.
Statistical analyses of the coprimary and other efﬁcacy end
points were described previously.2 Analysis-of-covariance
and analysis-of-variance models were used to determine if
there were residual effects of drug treatment on lipid
Figure 1. Effects of PHEN/TPM ER treatment on lipid variables and lipid-lowering medication use in the dyslipidemia subgroup. Least squares (LS) mean
percentage changes from baseline to week 56 in (A) weight, (B) high-density lipoprotein cholesterol (HDL-C), (C) triglycerides, and (D) non-HDL-C and (E)
net change (percentage increase minus percentage decrease) in concomitant lipid-lowering medications. *p <0.0001 versus placebo; †p <0.05 versus placebo;
xp ¼ 0.1803 for between-group comparisons. LOCF ¼ last observation carried forward.
Preventive Cardiology/Cardiovascular Beneﬁt of Phentermine/Topiramate ER 1133parameters and blood pressure after adjusting for weight loss.
The percentages of subjects achieving categorical weight loss
5%, 10%, and 15% were compared among treatment
groups using the chi-square test.
Results
Of the overall randomized population (N ¼ 2,487),
1,341 participants (53.9%) met criteria for dyslipidemia,
1,305 participants (52.5%) had hypertension, and 393(15.8%) had type 2 diabetes mellitus at baseline. Of the
randomized population, 18.5% (459 of 2,487) had triglyc-
erides <150 mg/dl but had high-density lipoprotein
cholesterol <40 to 50 mg/dl and low-density lipoprotein
cholesterol >160 mg/dl. These participants were not
considered as meeting criteria for dyslipidemia in the
present analysis. In total, 647 subjects (26.0%) had dysli-
pidemia and hypertension at baseline and were included in
the 2 subgroup analyses. Some differences in baseline
characteristics were seen between the overall sample and the
Figure 2. Effects of PHEN/TPM ER treatment on blood pressure (BP) and antihypertensive medications in the hypertensive subgroup. Least squares (LS) mean
percentage changes from baseline to week 56 in (A) weight, (B) systolic BP, and (C) diastolic BP and (D) net change (percentage increase minus percentage
decrease) in concomitant antihypertensive medication use. *p <0.0001 versus placebo; †p <0.05 versus placebo; xp <0.0001 for between-group comparisons.
LOCF ¼ last observation carried forward.
1134 The American Journal of Cardiology (www.ajconline.org)subgroups of participants in the present analyses in blood
pressure, lipid proﬁle, gender, and ethnicity (Table 1).
However, other baseline characteristics were similar across
treatment groups in each of these populations (data not
shown). In total, 147 participants (6.0%) in the overall pop-
ulation hadhistories of cardiac disorders, including histories of
myocardial infarction (37 [1.5%]), coronary artery disease (26
[1.1%]), arrhythmia (10 [0.4%]), angina pectoris (7 [0.3%]),
unstable angina (2 [0.1%]), and heart failure (3 [0.1%]).
The most common classes of lipid-controlling medications
used at baseline in participants with dyslipidemia were statins
(28.9%), ﬁbrates (5.9%), nicotinic acid and its derivatives
(3.5%), and bile-acid sequestrants (1.1%). The most common
antihypertensive medications used in participants with
hypertension at baseline were angiotensin-converting enzyme
inhibitors alone (26.9%) or in combination with diuretics
(5.8%) or calcium channel blockers (3.5%), b blockers alone
(24.1%), and angiotensin II antagonists alone (15.5%) or in
combination with diuretics (12.4%) or calcium channel
blockers (0.9%). Twenty-nine participants (2.4%) with dys-
lipidemia at baseline and 38 (3.0%) with hypertension at
baseline were taking aspirin at the beginning of the study.
Compared with placebo, PHEN/TPM ER produced
signiﬁcantly greater least squares mean percentage weightloss in the subgroup with dyslipidemia at baseline
(2.1%, 8.5%, and 10.5% for placebo, 7.5/46, and
15/92, respectively, p <0.0001; Figure 1) and in those with
hypertension at baseline (1.9%, 8.1%, and 10.1% for
placebo, 7.5/46, and 15/92, respectively, p <0.0001;
Figure 2). In addition, signiﬁcantly more participants
receiving PHEN/TPM ER achieved weight loss of
5%, 10%, and 15% compared with those receiving
placebo in the subgroup with dyslipidemia and in the
subgroup with hypertension (Supplemental Table 1).
Similar to the overall population,2 among participants
with dyslipidemia, there were signiﬁcant improvements with
PHEN/TPM ER versus placebo in serum high-density
lipoprotein cholesterol and triglyceride levels (Figure 1). In
this subanalysis, signiﬁcant improvements were also seen in
nonehigh-density lipoprotein cholesterol (Figure 1).
Importantly, improvements in these lipid variables were
greater with increasing degrees of weight loss, as were
improvements in inﬂammatory biomarkers (Table 2). No
clinically meaningful or statistically signiﬁcant differences
among treatment groups were observed in lipid parameters
after adjusting for degree of weight loss (data not shown). A
trend toward a net reduction in the percentage of participants
using lipid-lowering medications was also seen in the
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(p ¼ 0.1803 for between-group comparisons; Figure 1).
In line with the ﬁndings from the overall population,2
there were greater reductions from baseline in systolic blood
pressure and diastolic blood pressure in participants with
hypertension receiving PHEN/TPM ER compared with
placebo (Figure 2). Importantly, greater weight loss resulted
in greater improvements in blood pressure, regardless of
treatment group assignment (Table 3), with no signiﬁcant
differences between treatment groups in blood pressure
reduction after adjusting for degree of weight loss (data not
shown). However, no additional improvement was seen
when weight loss was 15%.
Compared with placebo, a greater percentage of PHEN/
TPM ERetreated participants with uncontrolled hyperten-
sion at baseline (140/90 mm Hg; placebo n ¼ 104, 7.5/46
n ¼ 40, and 15/92 n ¼ 72) achieved the blood pressure goal
of <140/90 mm Hg by week 56: 55 (52.9%) in the placebo
group, 25 (62.5%) in the 7.5/46 group, and 54 (75.0%) in
the 15/92 group (p ¼ 0.2996 for 7.5/46 vs placebo,
p ¼ 0.0034 for 15/92 vs placebo). Furthermore, in 11
(10.6%), 4 (10.0%), and 13 (18.1%) participants with
uncontrolled hypertension at baseline in the placebo, 7.5/46,
and 15/92 groups, respectively, blood pressure was
normalized to 120/80 mm Hg at 1 year. Use of concom-
itant antihypertensive drugs in participants with hyperten-
sion was reduced in PHEN/TPM ERetreated participants,
but there was a net increase in the use of antihypertensive
medications in the placebo group (p <0.0001 for between-
group comparisons; Figure 2).
The overall safety of treatment with PHEN/TPMER in the
entire population of the CONQUER trial was similar to that
observed in the subgroups presented here.2 Safety ﬁndings for
the overall population have been described fully elsewhere.2
In the subgroup with dyslipidemia, treatment-emergent
adverse events occurred in 75.9%, 86.5%, and 88.3% of the
placebo, 7.5/46, and 15/92 groups, respectively. In the
subgroup with hypertension, the rates were 77.3%, 85.4%,
and 88.8%, respectively. The most common treatment-
emergent adverse events in the subgroup with dyslipidemia
and the subgroup with hypertension were dry mouth, pares-
thesia, constipation, upper respiratory tract infection, and
nasopharyngitis (Table 4). The rates of serious adverse events
were similar among treatment groups (for placebo, 7.5/46,
and 15/92, in the subgroup with dyslipidemia, 4.3%, 4.0%,
and 3.8%, and in the subgroup with hypertension, 4.2%,
3.4%, and 3.7%, respectively). For the placebo, 7.5/46, and
15/92 groups, respectively, discontinuation because of
adverse events occurred in 8.8%, 12.4%, and 18.0% in the
subgroup with dyslipidemia and 9.7%, 11.9%, and 19.8% in
the subgroupwith hypertension. There was 1 death, occurring
in the placebo group of the subgroup with dyslipidemia.
In total, 3.8% of participants in the subgroup with dys-
lipidemia experienced treatment-emergent adverse events in
the cardiac disorders system-organ class (3.0%, 4.4%, and
4.3% in the placebo, 7.5/46, and 15/92 groups, respec-
tively). Most were reported as mild or moderate, with only
8 (0.6%) adverse events reported as severe. The only cardiac
treatment-emergent adverse event occurring in 1% of
participants with dyslipidemia was palpitations (0.9%,
2.9%, and 2.1% in the placebo, 7.5/46, and 15/92 groups,
Table 3
Effects of weight loss on blood pressure stratiﬁed by magnitude of weight loss for subjects with hypertension at baseline
Variable <5% Weight Loss
(n ¼ 657)
5% to <10% Weight Loss
(n ¼ 253)
10% to <15% Weight Loss
(n ¼ 177)
15% Weight Loss
(n ¼ 199)
Systolic blood pressure (mm Hg) 4.2 (5.2 to 3.2) 7.5 (9.2 to 5.9)* 10.8 (12.7 to 8.9)†,z 11.8 (13.6 to 10.0)†,x
Diastolic blood pressure (mm Hg) 3.1 (3.7 to 2.4) 5.9 (7.0 to 4.9)† 7.5 (8.8 to 6.3)† 7.4 (8.6 to 6.2)†
Data are least squares mean changes (intent to treat, last observation carried forward) with 95% conﬁdence intervals in parentheses.
* p ¼ 0.0007 versus <5% weight loss.
† p <0.0001 versus 5% weight loss.
z p ¼ 0.0116 versus 5% to <10% weight loss.
x p ¼ 0.0006 versus 5% to <10% weight loss.
Table 4
Most common treatment-emergent adverse events in the subgroups with dyslipidemia and hypertension
Adverse Event Subgroup With Dyslipidemia (ITT) Subgroup With Hypertension (ITT)
Placebo
(n ¼ 535)
PHEN 7.5 mg/TPM ER
46 mg (n ¼ 274)
PHEN 15 mg/TPM ER
92 mg (n ¼ 532)
Placebo
(n ¼ 524)
PHEN 7.5 mg/TPM ER
46 mg (n ¼ 261)
PHEN 15 mg/TPM ER
92 mg (n ¼ 520)
Dry mouth 1.1% 12.4% 21.6% 2.3% 14.2% 22.7%
Paresthesia 2.2% 13.5% 20.1% 2.3% 14.2% 22.3%
Constipation 5.0% 17.2% 16.5% 5.5% 15.7% 18.1%
Upper respiratory
tract infection
13.1% 11.3% 12.8% 11.8% 12.6% 12.1%
Nasopharyngitis 9.0% 9.5% 10.2% 8.8% 10.3% 10.2%
Dysgeusia 1.1% 8.8% 9.6% 0.8% 7.7% 11.0%
Insomnia 5.4% 5.8% 9.2% 4.8% 5.7% 11.0%
Headache 8.0% 9.5% 9.2% 8.4% 5.0% 10.8%
Dizziness 3.2% 7.3% 9.6% 3.1% 6.5% 12.1%
Sinusitis 5.4% 8.4% 9.4% 6.5% 5.4% 8.3%
ITT ¼ intent to treat.
1136 The American Journal of Cardiology (www.ajconline.org)respectively). Serious adverse cardiac events occurred in
11 participants (0.8%) with dyslipidemia, and serious
adverse vascular events occurred in 1 participant (0.1%)
with dyslipidemia. One participant with dyslipidemia in the
placebo group died from cardiopulmonary arrest (consid-
ered unrelated to the study drug).
In total, 2.6% of participants with hypertension experi-
enced treatment-emergent adverse events in the cardiac
disorders system-organ class (1.7%, 2.3%, and 3.7% in the
placebo, 7.5/46, and 15/92 groups, respectively). Most were
reported as mild or moderate, with only 5 adverse events
(0.4%) reported as severe. The only cardiac treatment-
emergent adverse event occurring in 1% of participants
with hypertension was palpitations (0.6%, 0.8%, and 1.2%
in the placebo, 7.5/46, and 15/92 groups, respectively).
Serious adverse cardiac events occurred in 6 participants
(0.5%) with hypertension, and serious adverse vascular
events occurred in 2 participants (0.2%) with hypertension.
Rates of serious adverse cardiac and vascular events in the
overall population were similar to those seen in the subgroups
(Supplemental Table 2). Mean changes in heart rate from
baseline to week 56 in the safety analysis were 0.5  10.2
beats/min (range 51 to 40), 0.1  10.8 beats/min
(range 42 to 34), and 1.3  10.3 beats/min (range 34 to
33) for the placebo, 7.5/46, and 15/92 groups, respectively, in
the subgroup with dyslipidemia and 0.2  10.1 beats/min
(range 51 to 40), 1.0  10.1 beats/min (range 42 to 38),
and 0.8  10.4 beats/min (range 31 to 33) for the placebo,
7.5/46, and 15/92 groups, respectively, in the subgroup withhypertension. Clinically signiﬁcant electrocardiographic
abnormalities according to investigator discretion were
observed in 1.0%, 0.4%, and 0.4% of those in the placebo,
7.5/46, and 15/92 groups, respectively, in the subgroup with
dyslipidemia and 1.7%, 1.4%, and 0.2% of those in the
placebo, 7.5/46, and 15/92 groups, respectively, in the
subgroup with hypertension. No other investigator-reported
clinically important differences in mean changes in electro-
cardiographic parameters were seen among the treatment
groups in either subgroup (Supplemental Table 3).
In the placebo, 7.5/46, and 15/92 groups, respectively,
hypokalemia was noted in 2 (0.4%), 6 (2.2%), and 9 (1.7%)
participants in the subgroup with dyslipidemia and 3 (0.6%),
5 (1.9%), and 26 (5.0%) participants in the subgroup with
hypertension. Persistence of potassium concentrations lower
than the lower limit of normal (<3.5 mmol/L at 2 consecutive
visits or at study exit) was seen in 6 (1.1%), 10 (3.7%), and
25 (4.7%) participants in the subgroup with dyslipidemia and
9 (1.7%), 15 (5.8%), and 40 (7.7%) participants in the
subgroup with hypertension. None of the cases of hypoka-
lemia was rated as severe, and percentages of participants
receiving potassium supplementation at any point during the
course of the study were comparable among groups (2.8% to
4.7% in the subgroup with dyslipidemia and 5.4% to 8.3% in
the subgroup with hypertension).2 In the placebo, 7.5/46, and
15/92 groups, respectively, persistence of low bicarbonate
concentrations (<21 mmol/L at 2 consecutive visits or at
study exit) was seen in 10 (1.9%), 18 (6.6%), and 48 (9.0%)
participants in the subgroup with dyslipidemia and in 11
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subgroup with hypertension. One (0.2%) and 4 (0.8%)
participants with dyslipidemia and 1 (0.2%) and 2 (0.4%)
participants with hypertension in the placebo and 15/92
groups, respectively, had persistently low bicarbonate
concentrations <17 mmol/L. In the 15/92 group, 1 partici-
pant (0.1%) with hypertension and 1 participant (0.2%) with
dyslipidemia showed a mild increase in serum chloride level.
Serum sodium showed a mild decrease in 1 participant
(0.2%) with dyslipidemia in the 15/92 group. One (0.2%)
placebo and 6 (1.1%) 15/92 participants with dyslipidemia
(not signiﬁcant vs placebo) and 1 (0.2%) placebo and 9
(1.7%) 15/92 participants with hypertension (p ¼ 0.0053 vs
placebo) had nephrolithiasis. Mild metabolic acidosis was
found as a treatment-emergent adverse event in 1 participant
(0.4%) with hypertension in the 7.5/46 group; no metabolic
acidosis events were observed in the dyslipidemia population.
Discussion
Treatment with PHEN/TPM ER has been shown to be
effective in promoting signiﬁcant weight loss in a dose-related
fashion compared with placebo over 56 weeks when used in
conjunction with lifestyle intervention.2 This subgroup anal-
ysis of participants who had dyslipidemia or hypertension at
baseline supports and extends this previous ﬁnding, demon-
strating that compared with placebo, PHEN/TPM ER treat-
ment leads to signiﬁcant weight loss accompanied by
signiﬁcant improvements in cardiovascular risk factors,
including blood pressure, lipid, and inﬂammatory biomarker
levels, as well as reductions in medication use. Importantly,
this study also demonstrated that increasing degrees of weight
loss up to 10% to 15% were associated with greater im-
provements in cardiovascular risk factors. These ﬁndings
demonstrate the potential beneﬁt of adding pharmacotherapy
to a weight-loss program that incorporates lifestyle changes in
the overall management of obese and overweight patients with
associated cardiometabolic conditions.
A positive relation between degree of weight loss and
magnitude of improvements in cardiovascular risk factors
has been previously demonstrated,14e16 while another study
has shown that differences in improvements in total and
low-density lipoprotein cholesterol were related to the
amount of weight lost and successfully maintained over the
long term (2 years).17 Speciﬁcally, in the Action for Health
in Diabetes (Look AHEAD) study, which assessed the
impact of lifestyle interventions resulting in modest weight
loss on cardiovascular risk factors in patients with type
2 diabetes, weight loss of 2% to <5% was associated with
improvements in some but not all risk factors measured,
weight loss of 5% to <10% led to signiﬁcant improve-
ments in all risk factors, and greater weight loss (10% to
<15%, and 15%) was associated with signiﬁcant and
increasing improvements in all cardiovascular risk factors
except low-density lipoprotein cholesterol.16 It is note-
worthy that only a small proportion of subjects in the Look
AHEAD study (<1% of the total population studied) lost
15% body weight when using lifestyle interventions.16
In the present study, participants showed incremental
improvements in cardiovascular risk factors with up to 10%
to 15% weight loss, but those with weight loss 15% didnot signiﬁcantly differ compared with those who lost 10%
to <15% of their body weight. However, it is difﬁcult to
draw any substantive conclusions, because the population
was relatively well controlled at baseline, and those who lost
10% to <15% of their body weight were within the
normotensive range at the end point, so additional incre-
mental and signiﬁcant improvements would be difﬁcult to
demonstrate in a study of this size and in this population.
Overall, changes in serum lipid levels associated with
PHEN/TPM ER use in participants with dyslipidemia at
baseline suggest that lipid parameters can be markedly
affected by weight loss.9,18 The reductions in nonehigh-
density lipoprotein cholesterol of approximately 10% to 15%
associatedwith PHEN/TPMEReinducedweight loss of5%
in patients already managed to standard of care were compa-
rable with the effect of ﬁbrate therapy for combined dyslipi-
demia.19 It appears that weight loss associated with PHEN/
TPM ER treatment confers approximately a 5% to 20%
increase in high-density lipoprotein cholesterol, depending on
the degree of weight loss, suggesting that PHEN/TPM ER is
a promising option for the treatment of overweight and obese
patients with an atherogenic dyslipidemic proﬁle. Although
not statistically signiﬁcant, it should be noted that these
improvements were seen despite a net numeric reduction
in the use of lipid-lowering medications over 56 weeks in
participants receiving PHEN/TPM ER compared with those
receiving placebo.
Of the participants with hypertension managed to stan-
dard of care at baseline, reductions in blood pressure were
observed along with signiﬁcant weight loss. The reduction
in blood pressure also occurred despite a net reduction in
the use of antihypertensive medications in PHEN/TPM
ERetreated participants. Furthermore, a greater proportion
of participants receiving PHEN/TPM ER with uncontrolled
hypertension (140/90 mm Hg) at baseline achieved blood
pressure control (<140/90 mm Hg) compared with those
receiving placebo, and 10% to 18% of participants receiving
PHEN/TPM ER and 11% of participants receiving placebo
normalized their blood pressure (120/80 mm Hg). This
ﬁnding is potentially signiﬁcant, because only half of the
United States population with hypertension is able to ach-
ieve adequate blood pressure control.20 In addition, such
reductions in medication burden are important, given that
multiple medications are often required by patients with
hypertension to achieve control.21
In line with the ﬁndings from the overall CONQUER
population,2 PHEN/TPM ER treatment was well tolerated in
participants who had hypertension or dyslipidemia at
baseline, with dry mouth, constipation, and paresthesia being
the most common adverse events. There was a dose-related
increase in discontinuation rates due to adverse events,
although discontinuations were infrequent overall (12%
to 20% for PHEN/TPM ER participants). In contrast with
the propensity of sympathomimetic weight-loss drugs
(e.g., sibutramine) to increase blood pressure and heart rate,22
PHEN/TPM ER weight loss was associated with a consistent
decrease in blood pressure, despite a small increase in heart
rate (0.1 to 1.3 beats/minute). Cardiac adverse events were
infrequent during the study for all treatment groups.
In the present study, PHEN/TPM ER treatment was
associated with more nonsevere hypokalemia and low
1138 The American Journal of Cardiology (www.ajconline.org)bicarbonate concentrations than lifestyle intervention alone,
but potassium supplementation across the study was
comparable among groups, and mild metabolic acidosis was
found in only 1 study participant.
This subanalysis had limitations. Primarily, the main study
included a broad population of obese participants and, as such,
was not powered to address outcomes related to particular
cardiovascular disease risk factors. However, although the
population in each co-morbidity subset was approximately
half the total study population, efﬁcacy and safety results were
comparable with those in the overall population.
Taken together, the dose-related weight loss induced by
PHEN/TPM ER, the associated beneﬁcial effects on car-
diometabolic risk factors, and the reductions in medication
use indicate that PHEN/TPM ER treatment may be an
important addition to the therapeutic armamentarium for
obese and overweight patients with co-morbidities such as
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